Discovering new drugs or receiving FDA approval for them are the glamor times for the pharmaceutical industry, but somewhere between the point of discovery and the marketplace is where most drug development goes to die.
Pipex Pharmaceuticals helps shepherd companies through this time. The Ann Arbor-based firm specializes in guiding life-science firms through the regulatory gauntlet and it has enjoyed a lot of home-grown success in the process. To wit, the firm is looking to add three people immediately.
"We're recruiting right now for several senior- and mid-level positions," says Nicholas Stergis, CEO of Pipex Pharmaceuticals. "We're still very much in the growth phase."
The company started with one person in 2001 and now has eight employees. Of those eight, three are former Pfizer workers. The company also brings in contractors on an as-needed basis.
"We were focuses on manufacturing and commercializing," Stergis says. "We have refocused the company on future products. We are pretty excited about some of our compounds."
Source: Nicholas Stergis, CEO of Pipex Pharmaceutical
Writer: Jon Zemke
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.